Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in ...

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...

Hope is on the horizon for patients living with chronic obstructive pulmonary disease (COPD). CHEST 2024 in Boston featured a session highlighting emerging bronchoscopic therapies.

COIMBATORE: A total of 1,039 people have been diagnosed with early Chronic Kidney Diseases (CKD) in Coimbatore district ...

Respiratory viruses can remain hidden in immune cells in the lungs long after the initial symptoms of an infection have ...

Symptoms and activity improved in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...

Study reveals that COVID-19 significantly increases the risk of chronic fatigue syndrome, with specific populations, such as ...

as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. Specifically, the approval covers patients ...